A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer

Prostate

Volumn 75, Issue 11, 2015, Pages 1206-1215

  Troyer, Dean A ^a,b   Jamaspishvili, Tamara ^c   Wei, Wei ^d   Feng, Ziding ^d   Good, Jennifer ^c   Hawley, Sarah ^e   Fazli, Ladan ^f   McKenney, Jesse K ^g   Simko, Jeff ^h,i   Hurtado Coll, Antonio ^f   Carroll, Peter R ⁱ   Gleave, Martin ^f   Lance, Raymond ^a   Lin, Daniel W ^j   Nelson, Peter S ^k   Thompson, Ian M ^b   True, Lawrence D ^l   Brooks, James D ^e   Squire, Jeremy A ^c,m  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

^l UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^m UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

active surveillance; biomarker; fluorescence in situ hybridization; Gleason score; PI3K PTEN Akt pathway; tissue array analysis

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GLEASON SCORE; HEMIZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE CANCER; PROSTATE CANCER EXTRACAPSULAR EXTENSION; PROTEIN BLOOD LEVEL; PTEN GENE; RECURRENCE FREE SURVIVAL; SEMINAL VESICLE DISEASE; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TUMOR INVASION; ADENOCARCINOMA; AGED; CANCER GRADING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; SEMINAL VESICLE;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SEMINAL VESICLES;

EID: 84932195056     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23003     Document Type: Article

References (45)

1. Eckersberger E, Finklestein J, Sadri H, Margreiter M, Taneja SS, Lepor H, Djavan B,. Screening for Prostate Cancer: A review of the ERSPC and PLCO Trials. Rev Urol 2009; 11: 127.
2. Kramer BS, Croswell JM,. Cancer screening: The clash of science and intuition. Annu Rev Med 2009; 60: 125.
3. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, deKoning H,. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374.
4. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325.
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A,.; ERSPC Investigators. Prosate-cancer mortality at 11 years of follow-up. NEJM 2012; 366: 981.
6. Cooperberg MR,. Will biomarkers save prostate cancer screening? European Urol 2012; 62: 962.
7. Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, EMberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schroder FH, Semhonow A, Trock BJ, Valdagni R,. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol 2013; 85: 295-302.
8. Dall'era MA, Albertsen PC, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway, MS., Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol 2012; 62: 976.
9. Punnen S, Freedland SJ, Presti JC, Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR,. Multi-institutiona validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol 2014; 65: 1171.
10. Epstein JI, Feng Z, Trock BJ, Pierorazio PM,. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012; 61: 1019-1024.
11. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR,. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2012; 29: 2795.
12. Treurniet KM, Trudel D, Sykes J, Evans AJ, Finelli A, Van der Kwast TH,. Downgrading of biopsy based Gleason score in prostatectomy specimens. J Clin Pathol 2014; 67: 313.
13. Cooke EW, Shrieve DC, Tward JD,. Clinical versus pathologic staging for prostate adenocarcinoma: How do they correlate? Am J Clin Onc 2012; 35: 364.
14. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ,. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869.
15. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME,. The critical role of the pathologist in determining elegibility for active surveillance as a management option in patients with prostate cancer. Arch Pathol Lab Med 2014; 138: 1387.
16. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S 1, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner S H, Giovanella BC, Itterman M, Tycko B, Hibshoosh H, Wigler M H, Parsons R,. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science (Washington DC), 1997; 275: 1943-1947.
17. Steck P A, Pershouse M A, Jasser S A, Yung W A K, Un H, Ligon A H, Langford L A, Baumgard M L, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng D H F, Tavtigian S V,. Identification of a candidate tumour suppressor gene, MMACI, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
18. Cairns P, Okami K, Halachmi S, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D,. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000.
19. Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM,. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol 2014; Jul DOI: 10.1038/modpathol.2014.85. Epub ahead of print
20. Yoshimoto M, Cunha IW, Coudry RA, et al., FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678.
21. Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS,. Molecular characterization of ERG, ETV2 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102: 678.
22. Krohn A, Diedler T, Burkhardt L. et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181: 401.
23. Sircar K, Yoshimoto M, Monzon FA, et al., PTEN genomic deletion is associated with p-Akt and AR signaling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 501.
24. Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA,. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011; 107: 477.
25. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z,. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: The Canary prostate cancer tissue microarray. Adv Anat Pathol 2013; 20: 39.
26. Yoshimoto M, Ludkovski O, Degrace D, Williams JL, Evans A, Sircar K, Bismar TA, Nuin P, Squire JA,. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 2012; 51: 149-160.
27. Edge SB, Byrd DR, Coompton CC, et al., editors. AJCC cancer staging manual, 7th ed. New York, NY: Springer; 2010.
28. Cookson MS, Aus G, Burnett AL, et al., Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in thereporting of surgical outcomes. J Urol 2007; 177: 540-545.
29. Egevad L, Mazzucchelli R, Montironi R,. Implications of the international society of urological pathology modified gleason grading system. Arch Pathol Lab Med 2012; 136: 426-434.
30. Ventura RA, Martin-Subero JI, Jones M, et al., FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 2006; 8 (2): 141.
31. Prensner JR, Chinnaiyan AM, Srivastava S,. Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis 2012; 29: 645.
32. Esserman LJ, Thompson IM, Reid B,. Overdiagnosis and overtreatment in cancer: An opportunity for improvement. JAMA 2013; 310: 797.
33. http://www.genomichealth.com/Pipeline/ProstateCancer.aspx#.UapIUZwQNWg
34. Song MS, Salmena L, Pandolfi PP,. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; Apr 4 13 (5): 283. PMID: 22473468 [PubMed - indexed for MEDLINE].
35. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM,. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860.
36. Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ,. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012; 25: 1543.
37. Fine SW, Gopalan A, Leversha MA, et al., TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010; 23: 1325.
38. Demichelis F, Rubin M,. A TMPRSS2-ETS fusion prostate cancer: Biological and clinical implications. J Clin Pathol 2007; 60: 1185.
39. Hermans KG, Boormans JL, Gasi D, et al., Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009; 20: 6398.
40. Hoogland AM, Kweldam CF, van Leenders GJ,. Prognostic histopathological and molecular markers on prostate cancer needle biopsies: A review. Biomed Res Int 2014; 2014: 341324.
41. Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, Joshua AM, Fleshner NE, Squire JA, Evans AJ,. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 2013; 26: 435.
42. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF,. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997.
43. Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lancbury JS, Stone S, Freedland SJ,. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol 2014; 12: 1209.
44. Villers AA, McNeal JE, Redwine EA, Freiha FS, Stamey TA,. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol 1990; 143: 1183.
45. Ohori M, Scadino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM,. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 1993; 17: 1252.